Latest & greatest articles for citalopram

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on citalopram or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on citalopram and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for citalopram

21. Citalopram, but not interpersonal psychotherapy, improves major depression in people with coronary artery disease

Citalopram, but not interpersonal psychotherapy, improves major depression in people with coronary artery disease Citalopram, but not interpersonal psychotherapy, improves major depression in people with coronary artery disease | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Citalopram, but not interpersonal psychotherapy, improves major depression in people with coronary artery disease Article Text Therapeutics Citalopram, but not interpersonal psychotherapy, improves major depression in people with coronary artery disease Statistics from

Evidence-Based Mental Health2008

22. Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study

Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study 18079286 2008 03 12 2008 03 28 2016 11 24 1468-3288 57 4 2008 Apr Gut Gut Therapy of interferon-induced depression in chronic hepatitis C with citalopram: a randomised, double-blind, placebo-controlled study. 531-6 Interferon-induced depression represents a major complication in antiviral treatment of chronic hepatitis C virus (HCV) infection. To evaluate (...) to placebo or citalopram (SSRI, 20 mg/day). In 28 patients (28%), HADS scores increased to >8 during interferon therapy. They were treated with placebo (n = 14) or SSRI (n = 14). HADS scores declined significantly in SSRI patients within four weeks of therapy (p<0.001) but not in placebo patients. This difference between subgroups was statistically significant (p = 0.032). Unblinding became necessary in five placebo patients as a result of intolerable depression. Rescue medication (20 mg citalopram) led

EvidenceUpdates2008

23. Citalopram-resistant depression: cognitive therapy and medication similarly effective as second line treatments

Citalopram-resistant depression: cognitive therapy and medication similarly effective as second line treatments Citalopram-resistant depression: cognitive therapy and medication similarly effective as second line treatments | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Citalopram-resistant depression: cognitive therapy and medication similarly effective as second line treatments Article Text Therapeutics Citalopram-resistant depression: cognitive therapy and medication similarly effective as second line treatments Free Sagar V Parikh

Evidence-Based Mental Health2008

24. Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study.

Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study. OBJECTIVE: To compare the risk of suicide in adults using the antidepressant venlafaxine compared with citalopram, fluoxetine, and dothiepin. DESIGN: Retrospective cohort study. SETTING: UK General Practice Research Database. PARTICIPANTS: 219,088 patients, aged 18-89 years, who were prescribed venlafaxine, citalopram, fluoxetine, or dothiepin from 1995 to 2005. MAIN OUTCOME (...) MEASURES: Completed suicide and attempted suicide. RESULTS: Venlafaxine users had a higher burden of risk factors for suicide, including previous suicide attempts and proxies for severe depression or depression that was difficult to treat. In the analysis for completed suicides, unadjusted and adjusted hazard ratios for venlafaxine compared with citalopram were 2.44 (95% confidence interval 1.12 to 5.31) and 1.70 (0.76 to 3.80), for venlafaxine compared with fluoxetine were 2.85 (1.37 to 5.94) and 1.63

BMJ2007 Full Text: Link to full Text with Trip Pro

25. Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder

Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder Fantino B, Moore N, Verdoux H, Auray J P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the relative cost-effectiveness of escitalopram (ESC) compared with citalopram (CIT) for the first-line treatment of patients aged 18 to 65 years with major depressive disorder. The authors concluded that ECS was the preferred strategy as it was more effective and less expensive than CIT from the perspective of the health care payer. The study methodology was of good quality

NHS Economic Evaluation Database.2007

26. A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care

A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary (...) care Sorensen J, Stage K B, Damsbo N, Le Lay A, Hemels M E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of escitalopram in comparison with generic citalopram and venlafaxine in the primary

NHS Economic Evaluation Database.2007

27. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial.

Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. 17244833 2007 01 24 2007 01 26 2016 10 17 1538-3598 297 4 2007 Jan 24 JAMA JAMA Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE (...) ) trial. 367-79 Few randomized controlled trials have evaluated the efficacy of treatments for major depression in patients with coronary artery disease (CAD). None have simultaneously evaluated an antidepressant and short-term psychotherapy. To document the short-term efficacy of a selective serotonin reuptake inhibitor (citalopram) and interpersonal psychotherapy (IPT) in reducing depressive symptoms in patients with CAD and major depression. The Canadian Cardiac Randomized Evaluation

JAMA2007

28. Mirtazapine plus citalopram has short term but not longer term benefits over citalopram alone for the symptoms of obsessive compulsive disorder

Mirtazapine plus citalopram has short term but not longer term benefits over citalopram alone for the symptoms of obsessive compulsive disorder Mirtazapine plus citalopram has short term but not longer term benefits over citalopram alone for the symptoms of obsessive compulsive disorder | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Mirtazapine plus citalopram has short term but not longer term benefits over citalopram alone for the symptoms of obsessive compulsive disorder Article Text Therapeutics Mirtazapine plus citalopram has short term

Evidence-Based Mental Health2006

29. Major depressive disorder: similar remission rates with bupropion, sertraline, or venlafaxine following treatment switch from citalopram

Major depressive disorder: similar remission rates with bupropion, sertraline, or venlafaxine following treatment switch from citalopram Major depressive disorder: similar remission rates with bupropion, sertraline, or venlafaxine following treatment switch from citalopram | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional (...) accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Major depressive disorder: similar remission rates with bupropion, sertraline, or venlafaxine following treatment switch from citalopram Article Text Therapeutics Major depressive disorder: similar remission rates

Evidence-Based Mental Health2006

30. A cost-effectiveness model of escitalopram, citalopram, and venlafaxine as first-line treatment for major depressive disorder in Belgium

A cost-effectiveness model of escitalopram, citalopram, and venlafaxine as first-line treatment for major depressive disorder in Belgium A cost-effectiveness model of escitalopram, citalopram, and venlafaxine as first-line treatment for major depressive disorder in Belgium A cost-effectiveness model of escitalopram, citalopram, and venlafaxine as first-line treatment for major depressive disorder in Belgium Demyttenaere K, Hemels M E, Hudry J, Annemans L Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The health technologies compared were escitalopram (10 - 20 mg/day), citalopram (20 - 40 mg/day) and venlafaxine (75 - 150 mg/day) as first-line treatment for major depressive disorder (MDD). MDD was defined as baseline

NHS Economic Evaluation Database.2005

31. A pharmacoeconomic evaluation of escitalopram versus citalopram in the treatment of severe depression in the United Kingdom

A pharmacoeconomic evaluation of escitalopram versus citalopram in the treatment of severe depression in the United Kingdom A pharmacoeconomic evaluation of escitalopram versus citalopram in the treatment of severe depression in the United Kingdom A pharmacoeconomic evaluation of escitalopram versus citalopram in the treatment of severe depression in the United Kingdom Wade A G, Toumi I, Hemels M E H Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Escitalopram was compared with citalopram for the treatment of severe depression. The dose of escitalopram was 20 mg/day and that of citalopram 40 mg/day. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The target population

NHS Economic Evaluation Database.2005

32. A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK

A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK Wade A G, Toumi (...) I, Hemels M E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Three therapies for the treatment of major depressive disorder (MDD) were examined. These were escitalopram (ESC; 10 - 20 mg daily), citalopram (CIT; 20 - 40 mg

NHS Economic Evaluation Database.2005

33. Citalopram therapy for depression: a review of 10 years of European experience and data from US clinical trials

Citalopram therapy for depression: a review of 10 years of European experience and data from US clinical trials Citalopram therapy for depression: a review of 10 years of European experience and data from US clinical trials Citalopram therapy for depression: a review of 10 years of European experience and data from US clinical trials Keller M B Authors' objectives To review a decade of experience with citalopram, focusing mainly on efficacy, safety, and tolerability data derived from randomised (...) , well-controlled clinical trials of patients with depression. Searching MEDLINE was searched from 1966 to 2000 to identify relevant English language publications, using the following terms: 'citalopram', 'SSRI', 'TCA', 'depression' and 'clinical'. Published biographies were cross-referenced to locate additional primary sources of information. Data presented at major medical conferences and published in abstract form were also reviewed. Study selection Study designs of evaluations included

DARE.2000

34. A Markov process analysis comparing the cost effectiveness of maintenance therapy with citalopram versus standard therapy in major depression

A Markov process analysis comparing the cost effectiveness of maintenance therapy with citalopram versus standard therapy in major depression A Markov process analysis comparing the cost effectiveness of maintenance therapy with citalopram versus standard therapy in major depression A Markov process analysis comparing the cost effectiveness of maintenance therapy with citalopram versus standard therapy in major depression Nuijten M J, Hardens M, Souetre E Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Pharmaceutical: citalopram, doxepin (Sinquan), doxepin (Aponal), trimipramine (Stangyl), amitriptyline (Saroten). Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study

NHS Economic Evaluation Database.1995

35. Citalopram for post-stroke pathological crying.

Citalopram for post-stroke pathological crying. 8104273 1993 10 21 1993 10 21 2015 06 16 0140-6736 342 8875 1993 Oct 02 Lancet (London, England) Lancet Citalopram for post-stroke pathological crying. 837-9 Post-stroke pathological crying is a distressing condition in which episodes occur in response to minor stimuli without associated mood changes. There is preliminary evidence of disturbed serotoninergic neurotransmission in such cases. We investigated the effect (...) of the selective serotonin reuptake inhibitor citalopram on uncontrolled crying in stroke patients in a double-blind placebo-controlled crossover study. 16 consecutive patients (median age 58.5 years, range 40-83) entered the 9-week study a median of 168 days (range 6-913) post stroke and were treated with citalopram 10-20 mg daily for 3 weeks. Crying history was determined from semistructured interviews and from diaries kept by the patients. Psychiatric assessment was made with the Hamilton depression scale (HDS), and unwanted effects

Lancet1993